Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Common Equity (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Common Equity readings, the most recent being $198.3 million for Q1 2026.

  • Quarterly Common Equity rose 234.48% to $198.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $198.3 million through Mar 2026, up 234.48% year-over-year, with the annual reading at $130.7 million for FY2025, 91.51% up from the prior year.
  • Common Equity hit $198.3 million in Q1 2026 for Ovid Therapeutics, up from $130.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $198.3 million in Q1 2026 and bottomed at $44.7 million in Q3 2025.
  • Average Common Equity over 5 years is $106.6 million, with a median of $101.3 million recorded in 2023.
  • The largest annual shift saw Common Equity tumbled 41.41% in 2025 before it soared 234.48% in 2026.
  • Ovid Therapeutics' Common Equity stood at $132.3 million in 2022, then crashed by 33.62% to $87.8 million in 2023, then decreased by 22.29% to $68.2 million in 2024, then surged by 91.51% to $130.7 million in 2025, then surged by 51.74% to $198.3 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Common Equity are $198.3 million (Q1 2026), $130.7 million (Q4 2025), and $44.7 million (Q3 2025).